{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Amryt Pharma plc"},"Symbol":{"label":"Symbol","value":"AMYT"},"Address":{"label":"Address","value":"196 HIGH ROAD DEPT 920A, WOOD GREEN, LONDON, N22 8HH, United Kingdom"},"Phone":{"label":"Phone","value":"+44 2030267257"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA)."},"CompanyUrl":{"label":"Company Url","value":"http://www.amrytpharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Joseph A. Wiley","title":"Chief Executive Officer &amp; Director"},{"name":"Rory Peter Nealon","title":"Secretary, Chief Financial &amp; Operating Officer"},{"name":"Tracy Cunningham","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}